

REGENERON PHARMACEUTICALS INC
Form 10-Q
August 04, 2016

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 10-Q

(Mark One)

QUARTERLY

REPORT

PURSUANT

TO SECTION

13 OR 15(d)

OF THE

SECURITIES

EXCHANGE

ACT OF 1934

For the

quarterly

period

ended June

30, 2016

OR

TRANSITION

REPORT

PURSUANT

TO SECTION

13 OR 15(d)

OF THE

SECURITIES

EXCHANGE

ACT OF 1934

For the

transition

period from

_____ to

Commission File Number 0-19034

REGENERON PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

New York

(State or other jurisdiction of

incorporation or organization)

13-3444607

(I.R.S. Employer Identification No.)

777 Old Saw Mill River Road, Tarrytown, New York

(Address of principal executive offices)

10591-6707

(Zip Code)

(914) 847-7000

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 10-Q

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer", "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer (Do not check if a smaller reporting company) Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes No

Number of shares outstanding of each of the registrant's classes of common stock as of July 14, 2016:

| Class of Common Stock | Number of Shares |
|---------------------------------|------------------|
| Class A Stock, \$.001 par value | 1,911,456 |
| Common Stock, \$.001 par value | 103,383,050 |

Table of Contents

REGENERON PHARMACEUTICALS, INC.
 QUARTERLY REPORT ON FORM 10-Q
 TABLE OF CONTENTS

| | Page Numbers |
|---|-----------------|
| <u>PART I FINANCIAL INFORMATION</u> | |
| <u>Item 1. Financial Statements (unaudited)</u> | <u>2</u> |
| <u>Condensed Consolidated Balance Sheets as of June 30, 2016 and December 31, 2015</u> | <u>2</u> |
| <u>Condensed Consolidated Statements of Operations and Comprehensive Income for the Three and Six Months Ended June 30, 2016 and 2015</u> | <u>3</u> |
| <u>Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2016 and 2015</u> | <u>4</u> |
| <u>Notes to Condensed Consolidated Financial Statements</u> | <u>5</u> |
| <u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u> | <u>22</u> |
| <u>Item 3. Quantitative and Qualitative Disclosures About Market Risk</u> | <u>52</u> |
| <u>Item 4. Controls and Procedures</u> | <u>53</u> |
| <u>PART II OTHER INFORMATION</u> | |
| <u>Item 1. Legal Proceedings</u> | <u>53</u> |
| <u>Item 1A. Risk Factors</u> | <u>54</u> |
| <u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</u> | <u>82</u> |
| <u>Item 6. Exhibits</u> | <u>84</u> |
| <u>SIGNATURE PAGE</u> | <u>85</u> |

"ARCALYST®", "EYLEA®", "ZALTRAP®", "VelocImmune®", "VelociGene®", "VelociMouse®", "VelociMab®", and "VelociSuite®" are trademarks of Regeneron Pharmaceuticals, Inc. Trademarks and trade names of other companies appearing in this report are, to the knowledge of Regeneron Pharmaceuticals, Inc., the property of their respective owners.

Table of ContentsPART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTSREGENERON PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)
(In thousands, except share data)

| | June 30, 2016 | December 31, 2015 |
|---|------------------|-------------------------|
| ASSETS | | |
| Current assets: | | |
| Cash and cash equivalents | \$646,508 | \$809,102 |
| Marketable securities | 398,656 | 236,121 |
| Accounts receivable - trade, net | 1,431,966 | 1,152,489 |
| Accounts receivable from Sanofi | 138,067 | 153,152 |
| Accounts receivable from Bayer | 181,938 | 162,152 |
| Inventories | 316,073 | 238,578 |
| Prepaid expenses and other current assets | 96,017 | 163,501 |
| Total current assets | 3,209,225 | 2,915,095 |
| Marketable securities | 589,852 | 632,162 |
| Property, plant, and equipment, net | 1,772,923 | 1,594,120 |
| Deferred tax assets | 626,191 | 461,945 |
| Other assets | 6,715 | 5,810 |
| Total assets | \$6,204,906 | \$5,609,132 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | | |
| Current liabilities: | | |
| Accounts payable and accrued expenses | \$759,643 | \$644,112 |
| Deferred revenue from Sanofi, current portion | 104,141 | 101,573 |
| Deferred revenue - other, current portion | 84,084 | 51,914 |
| Other current liabilities | 3,695 | 13,563 |
| Total current liabilities | 951,563 | 811,162 |
| Deferred revenue from Sanofi | 549,342 | 582,664 |
| Deferred revenue - other | 146,449 | 82,015 |
| Facility lease obligations | 361,523 | 362,919 |
| Other long-term liabilities | 119,523 | 115,535 |
| Total liabilities | 2,128,400 | 1,954,295 |
| Stockholders' equity: | | |
| Preferred stock, \$.01 par value; 30,000,000 shares authorized; issued and outstanding - none— | — | — |
| Class A Stock, convertible, \$.001 par value; 40,000,000 shares authorized; shares issued and outstanding - 1,911,456 in 2016 and 1,913,776 in 2015 | 2 | 2 |
| Common Stock, \$.001 par value; 320,000,000 shares authorized; shares issued - 107,132,543 in 2016 and 106,378,001 in 2015 | 107 | 106 |
| Additional paid-in capital | 3,156,942 | 3,099,526 |
| Retained earnings | 1,230,303 | 852,700 |

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 10-Q

| | | |
|---|------------|------------|
| Accumulated other comprehensive income | 5,204 | 8,572 |
| Treasury stock, at cost; 3,761,628 shares in 2016 and 3,642,820 in 2015 | (316,052) | (306,069) |
| Total stockholders' equity | 4,076,506 | |